The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungsDemonstrated >90% editing of SER ...
Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of ...
From left to right: Ascidian Therapeutics' Chief Financial & Business Officer Dan Rosan, Senior Vice President and Head of Research Robert Bell, and Chief Medical Officer Jay Barth. Biotechnology ...
The new CRISPR platform, called ΨDNA, reprograms Cas12 nucleases to recognize and act on RNA using a DNA-based guide scaffold ...
Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...
After becoming the first group to therapeutically edit human RNA in October 2024, Wave Life Sciences has released more data from its ongoing alpha-1 antitrypsin deficiency (AATD) clinical trial—and ...
Researchers developed ΨDNA, a DNA-based CRISPR guide that allows Cas12 enzymes to target RNA with high specificity while ...
The most recent developments in the field of A-to-I RNA modification, with a special emphasis on the roles of A-to-I in the genesis and progression of cancer. Adenosine-to-inosine (A-to-I) RNA editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results